Weight Loss Drug Price Storm: Semaglutide Generics Monthly Cost Might Drop to $15

Goldman Sachs held a closed-door meeting on the GLP-1 field on May 8, 2026, with the core judgment that semaglutide is undergoing a transformation in identity – shifting from a "high-end out-of-pocket therapy" to a "mass-market chronic disease drug." The biggest beneficiary of this shift is not at the formulation terminal but in the upstream supply chain.

The true cost of producing a semaglutide injection pen reveals the endgame of this price war. With the price of the active pharmaceutical ingredient (API) plummeting to between $102 and $150 per gram, the cost for the API in each pen containing a 2.4mg dose is only $1 to $1.5, the pen material is approximately $1.5, and the filling and processing cost is between $0.1 and $0.2, making the total production cost about $9 to $14. This directly caps future pricing: generic drugs will be priced below $50 per month at the beginning of their launch, and small molecule generics will approach $10 to $15 per month in maturity. When the monthly cost drops below $30, price will no longer be a barrier, and the "volume replaces value" logic will take over the market completely.

China is the most important battlefield in the next decade. The number of GLP-1 treated individuals is expected to surge 25-fold from a penetration rate of 0.3% in 2025 to 35 million people by 2035. The market size is forecasted to reach a peak of $5 billion in 2029 and then decline to $3.5 billion following the increase in generic penetration. The market structure will show a dual-track divergence: basic chemical generics and high-end differentiated products each accounting for about 50%. Referring to the historical patterns of statins and PDE5 inhibitors, only 1 to 2 companies might be able to secure more than 30% of the generic drug track. East China Pharmaceutical, GreenLeaf Pharmaceutical, United Laboratories, and Stone Pharmaceutical Group are the fastest in their progress and are expected to be approved in April 2027 at the same time. The barriers in the high-end track are focused on oral GLP-1 (expected to account for 30% of the Chinese market share, led by Eli Lilly) and new indications such as cardiovascular and liver fat reduction – drugs that can provide combined clinical benefits will continue to enjoy a premium.

On the supply chain side, there has been a clear surplus of basic API. China's peptide API production capacity exceeds 25,000 kilograms, which theoretically is enough for 400 million people to use for 7 days. However, there is still a structural shortage in high-quality peptides and oral medicine capacity, and profits are concentrated towards CDMOs with complex processing and scaled capabilities. WuXi AppTec is deeply integrated with global innovative pipelines, maintaining a high growth guidance of 40% for 2026, and the impact of the "Biosafety Act" is considered to have been largely factored into the valuation; Kaitai Pharmaceutical is expected to reach a capacity of 69,000 liters by year-end; Kangle Pharmaceutical has become an emerging beneficiary due to a strategic cooperation with Eli Lilly on oral formulations; and injection pen supplier Weigao Corporation's production capacity is planned to jump from 5 to 6 million pens in 2025 to 40 million pens in 2027.

In terms of global outreach, patents in the European and American markets will not expire until 2031 to 2032, making Latin America, the Middle East, and Southeast Asia the current areas of contention. The Indian market has already taken off, with generics launching in March 2026, 13 companies launching 26 brands within just 10 days, and generics quickly capturing a 24% market share, with the scale expected to reach $1.5 billion by fiscal year 2031. The core challenge for Chinese companies is to complete the improvement of production utilization and GMP compliance within the next 5 to 6 years in order to gain an advantageous position in the competition after the expiration of patents in Europe and America.